| Dr Kristi Ann Payne, PHARMD | |
|
790 Schillinger Rd S, Mobile, AL 36695-8979 | |
| (251) 776-1512 | |
| Not Available |
| Full Name | Dr Kristi Ann Payne |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 790 Schillinger Rd S, Mobile, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033524376 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 17716 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kristi Ann Payne, PHARMD 790 Schillinger Rd S, Mobile, AL 36695-8979 Ph: (251) 776-1512 | Dr Kristi Ann Payne, PHARMD 790 Schillinger Rd S, Mobile, AL 36695-8979 Ph: (251) 776-1512 |
News Archive
A team of scientists reports that a small molecule compound showed significant success in controlling the infectivity and spread of three polyomaviruses in human cell cultures. To date there has been no medicine approved to treat such viruses, which prey on transplant recipients, people with HIV, and others whose immune systems have been weakened.
The Federal Trade Commission said that it is mailing refund checks to 13,000 Medicare Part D beneficiaries who were overcharged for drugs because a CVS Caremark Corp. business understated the price of the medications.
Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.
Today's health policy headlines include news about how the debt panel's plan would boost costs for seniors on Medicare; how parts of the GOP are making clear their positions regarding health reform "repeal and replace" strategy; and how limited health plans faced critics at a Senate hearing.
› Verified 1 days ago
Dr. Wilfred Arcard Brown, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3948 Airport Blvd, Mobile, AL 36608 Phone: 251-345-3394 | |
Chidiya Ohiagu, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1303 Dr Martin L King Jr Ave, Mobile, AL 36603 Phone: 251-432-4117 | |
Darren P Billiot, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6575 Airport Blvd, Mobile, AL 36608 Phone: 251-370-9848 | |
Eric Donaldson Reeves, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4628 Airport Blvd, Mobile, AL 36608 Phone: 251-341-5749 | |
Mr. Chuck P Whisonant, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1504 Spring Hill Ave, Mobile, AL 36604 Phone: 251-219-3754 | |
Ms. Angela F. Amos, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 251 N Bayou St, Mobile, AL 36603 Phone: 251-690-8817 | |
Dr. Raymond Lorenz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2400 Gordon Smith Dr, Mobile, AL 36617 Phone: 251-450-1388 |